Amgen is a leading biotechnology company based in the United States. Founded in 1980 by venture capitalist William K. Bowes Jr., it has its headquarters in Thousand Oaks, California.

Amgen's main focus is on discovering, developing, and delivering human therapeutics. The company’s mission is to serve patients by transforming the promise of biotechnology into medicines that significantly improve their lives. Amgen's product portfolio includes a wide range of innovative biologic medicines.

These products primarily target oncology, nephrology, inflammation, cardiovascular, and bone health therapeutic areas. Notable products from Amgen include Enbrel (etanercept) for rheumatoid arthritis and psoriasis, Neulasta (pegfilgrastim) for neutropenia, and Prolia (denosumab) for osteoporosis. Additionally, Amgen is a major player in the development of biosimilars, which are similar versions of biological medicines that offer potentially lower-cost alternatives to patients.

Operating on a global scale, Amgen has a significant presence in various markets around the world. The company has several wholly-owned subsidiaries, including Amgen International, Amgen Manufacturing Ltd, and Amgen Australia. Amgen also has numerous joint ventures and partnerships to expand its reach and collaborate with other industry leaders.

With its strong product lineup and global presence, Amgen holds a prominent market position in the biotechnology industry. It consistently ranks among the top biotechnology companies in terms of revenue and market capitalization. The company has a robust research and development pipeline, focusing on innovative therapies that address patient needs across a broad range of diseases.

Amgen has achieved several significant milestones and made strategic changes to fuel its growth. In recent years, the company has expanded its biosimilar portfolio and ventured into gene therapy through partnerships and acquisitions. These strategic moves demonstrate Amgen's commitment to advancing medical science and delivering novel therapies to patients worldwide.

As of the latest updates, Amgen continues to focus on innovation and expanding its pipeline. The company is dedicated to pioneering breakthrough treatments through cutting-edge research and development initiatives. Amgen is also committed to upholding its core values, including a strong commitment to ethics, responsibility, and environmental sustainability.

With its continued growth and commitment to improving patient lives, Amgen is poised to maintain its position as a leader in the biotechnology industry